Tavio Capital LLC Sells 85,077 Shares of Alexion Pharmaceuticals, Inc. (ALXN)

Tavio Capital LLC reduced its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 51.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 79,856 shares of the biopharmaceutical company’s stock after selling 85,077 shares during the quarter. Alexion Pharmaceuticals comprises about 4.3% of Tavio Capital LLC’s portfolio, making the stock its 9th biggest position. Tavio Capital LLC’s holdings in Alexion Pharmaceuticals were worth $11,101,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ALXN. First Hawaiian Bank acquired a new position in Alexion Pharmaceuticals in the third quarter valued at approximately $102,000. Advisory Services Network LLC lifted its holdings in Alexion Pharmaceuticals by 145.3% in the second quarter. Advisory Services Network LLC now owns 883 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 523 shares during the period. Columbia Asset Management acquired a new position in Alexion Pharmaceuticals in the third quarter valued at approximately $138,000. Checchi Capital Advisers LLC acquired a new position in Alexion Pharmaceuticals in the third quarter valued at approximately $204,000. Finally, K.J. Harrison & Partners Inc acquired a new position in Alexion Pharmaceuticals in the third quarter valued at approximately $209,000. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ:ALXN traded up $1.83 during midday trading on Monday, reaching $119.93. 105,506 shares of the company were exchanged, compared to its average volume of 1,221,663. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $102.10 and a fifty-two week high of $140.77. The company has a quick ratio of 2.74, a current ratio of 3.16 and a debt-to-equity ratio of 0.32. The firm has a market cap of $26.35 billion, a price-to-earnings ratio of 23.24, a PEG ratio of 1.02 and a beta of 0.99.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Wednesday, October 24th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.74 by $0.28. Alexion Pharmaceuticals had a net margin of 3.90% and a return on equity of 16.60%. The business had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period last year, the business posted $1.44 earnings per share. The firm’s quarterly revenue was up 19.5% on a year-over-year basis. Research analysts expect that Alexion Pharmaceuticals, Inc. will post 6.82 earnings per share for the current fiscal year.

ALXN has been the topic of several analyst reports. BidaskClub lowered shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 9th. Barclays increased their target price on shares of Alexion Pharmaceuticals to $175.00 and gave the stock an “overweight” rating in a report on Friday, September 28th. ValuEngine upgraded shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, November 8th. Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 13th. Finally, Morgan Stanley increased their target price on shares of Alexion Pharmaceuticals from $157.00 to $165.00 and gave the stock an “overweight” rating in a report on Thursday, October 11th. Four analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $161.50.

WARNING: “Tavio Capital LLC Sells 85,077 Shares of Alexion Pharmaceuticals, Inc. (ALXN)” was first published by WKRB News and is owned by of WKRB News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.wkrb13.com/2018/11/26/tavio-capital-llc-sells-85077-shares-of-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Featured Article: Understanding the different types of bonds

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply